Clinical Trial Update: Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers [Phase 2]

View source ↗

Summary

Phase 2a study of HU6 in subjects with elevated liver fat and high BMI related to nonalcoholic steatohepatitis (NASH) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• HU6

Snippet

Sponsor: Rivus Pharmaceuticals, Inc. | Conditions: NASH - Nonalcoholic Steatohepatitis | Phase 2 | Status: COMPLETED | Results posted: 2024-03-01